Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Liposomes
Reexamination Certificate
1999-12-21
2004-09-07
Schwadron, Ronald B. (Department: 1644)
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Liposomes
C424S138100, C424S142100, C424S155100, C424S174100, C424S133100, C424S134100, C530S387700, C530S388150, C530S388800, C530S865000, C530S867000, C530S866000, C530S389700, C530S387100, C530S391100, C530S391700
Reexamination Certificate
active
06787153
ABSTRACT:
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates to a novel human monoclonal antibody useful for diagnosis and therapy of cancer, an isolated DNA encoding the monoclonal antibody, and a hybridoma producing the antibody. The present invention also relates to an anti-cancer formulation comprising the antibody bonded to a liposome which contains an anti-cancer agent.
2. Description of Related Art
There has been no anti-cancer formulation thus far, which is sufficiently effective for the treatment of solid cancer. On the other hand, there has long existed an idea called “targeting” in which a therapeutical agent is concentrated at a tissue or an organ to be treated in order to maximize the therapeutical effect of the agent. Accordingly, it has been expected that focusing an anti-cancer agent at a cancer tissue by means of “targeting” may allow a therapy of the solid cancer. A number of trials to concentrate an anti-cancer agent or a toxin at a cancer tissue were made since a method for production of mouse monoclonal antibodies in large quantities has been established by Milstein and Köhler (Nature, 1975), and some of them were successful.
Thus far, binding of an antibody to a therapeutic agent has been accomplished by directly binding an antibody to a chemically-modified therapeutic agent, or indirectly binding them via a water-soluble polymer such as dextran. These methods, however, have drawbacks in that the amount of a therapeutic agent capable of binding to one antibody molecule is very limited, and in that chemical modification of a therapeutic agent often causes lowering of the therapeutical activity. As one of the countermeasures to overcome the drawbacks, there was proposed a new delivery system which consists of an antibody bonded to the surface of a liposome in which a therapeutic agent is encapsuled, and many favorable results were reported (Konno et al, Cancer Research 47 4471, 1987; Hashimoto et al, Japanese Patent Publication (unexamined) No. 134032/1983).
However, mouse monoclonal antibodies have a limited clinical use and continued administration thereof is impossible from a practical point of view due to side effects such as anaphylaxis caused by immune response (See A. Lo Bugli et al, Proc. Natl. Acad. Sci. U.S.A., 86 4220, 1989). Accordingly, human monoclonal antibodies rather than mouse monoclonal antibodies are preferable for the purpose of clinical use. However, preparation of human monoclonal antibodies which adequately react with cancer cells has long been considered very difficult because of the reasons that it is very difficult to conduct passive immunity for the purpose of obtaining human B cells which produce a desired antibody, and that any efficient methodology which allows infinite reproduction of antibody-producing cells has not been established yet.
In such a situation as mentioned above, the inventors of the present invention have made extensive study for the purpose of obtaining a human monoclonal antibody which permits “targeting therapy” on cancer tissue or organ with the help of anti-cancer agents or toxins, and they have succeeded in preparing a hybridoma capable of producing a novel human monoclonal antibody, the antigen to which exists on the surface of cell membrane of cancer cells. They also have succeeded in preparing a therapeutical formulation useful for “targeting therapy” of cancer, by binding the monoclonal antibody of the invention to a liposome in which an anti-cancer agent is encapsuled. The present invention p based on these findings.
SUMMARY OF THE INVENTION
Thus, the present invention provides a human monoclonal antibody specific to an antigen existing on the surface of a cancer cell membrane, said monoclonal antibody being produced by a fused cell between a lymphocyte derived from cancer patient and a mouse myeloma cell. The invention further provides an isolated gene encoding the antibody, a hybridoma producing the antibody, and an anti-cancer formulation containing the antibody.
The human monoclonal antibodies of the present invention contain, in the variable region of the heavy chain, the amino acid sequences shown, for instance, in Sequence Listing Nos. 13, 14, and 15. More specifically, the monoclonal antibodies of the invention include, among others, those in which the variable region of the heavy chain comprises the amino acid sequences shown in Sequence Listing Nos. 16, 17, and 18, and the variable region of the light chain comprises the amino acid sequences shown in Sequence Listing Nos. 19, 20, and 21, and those in which the variable region of the heavy chain comprises the amino acid sequences given in Sequence Listing Nos. 22, 23, and 24, and the variable region of the light chain comprises the amino acid sequences given in Sequence Listing Nos. 25, 26, and 27.
The monoclonal antibodies of the invention include any variants of the above-mentioned specific antibodies, which are obtainable by making insertion, deletion, substitution and/or addition of one or more amino acid residues to the amino acid sequences of the above-identified antibodies with the limitations that such modification must not adversely affect the reactivity of the antibodies against the antigens. The present invention will be more detailed below.
REFERENCES:
patent: 4800155 (1989-01-01), Taniguchi et al.
patent: 5024946 (1991-06-01), Abe et al.
patent: 5093261 (1992-03-01), Hagiwara et al.
patent: 5264221 (1993-11-01), Tagawa et al.
patent: 0 178 891 (1987-09-01), None
patent: 9014595 (1990-11-01), None
patent: 9109134 (1991-06-01), None
patent: 9116071 (1991-10-01), None
Morrison, Ann. Rev. Immunol., 10:239-65, 1992.
Jain, Sci. Amer., 271(1):58-65, 1994.
Curti, Crit. Rev. in Oncol./Hematol. 14, 29-39, 1993.
Oshbund et al., Imm. Today, 11: 193-195, 1990.
Chemical Astracts, vol. 111, No. 13, Sep. 25, 1989, Columbus, Ohio USA Kazuhiro Yoshikawa et al., “A Human Monoclonal Antibody Recognizing a Surface Antigen on Stomach Cancer Cells.”, p. 503, column 2, Abstract-no. 113 362y.
Chemical Abstracts, vol. 100, No. 21, May 21, 1984, Columbus, Ohio, USA, Takashi Masuko et al., “Monoclonal Antibodies Against Cell Surface Antigens Present on Human Urinary Bladder Cancer Cells.”, p. 474, Column 1, Abstract-no. 172 850b.
Dermer, Bio/Technology, 12: 320, 1994.
Cancer Research vol. 45, 263-271, Jan. 1985, Imam et al., “Generation and Immunohistological Characterization of Human Monoclonal Antibodies to Mammary Carcinoma Cells”.
Cancer Immunol/Immunotherapy (1989) 28: 296-300, Formenti et al., “Reactivity of a Human Monoclonal Antibody Against Carcinomas and other Lesions of the Colon”.
Cancer Research vol. 49, 2471-2476, May 1, 1989, Vollmers et al., “SC-1 a Functional Human Monoclonal Antibody Against Autologous Stomach Carcinoma Cells”.
Cell vol. 22, 197-207, Nov. 1980, Hieter et al. “Cloned Human and Mouse Kappa Immunoglobulin Constant and J. Region Genes Conserve Homology in Functional Segments”.
Nature vol. 294, 536-540, Hieter et al., “Clustered Arrangement of Immunoglobulin Constant Region Genes in Man” Dec. 10, 1981.
The Journal of Biological Chemistry vol. 257, 1516-1522, Feb. 1992, Hieter et al., “Evolution of Human Immunoglobulin k J. Region Genes”.
Nucleic Acids Research, vol. 14, 1779-1789, Huck et al., Sequence of a Human immunoglobulin Gamma 3 heavy chain constant region gene: comparison with the other human C genes (1986).
Nucleic Acids Research, vol. 18, 4278, May 1990, Friedlander et al., Complete nucleotide sequence of the membrane form of the human lgM heavy chain.
Nature vol. 321, 522-525, May 1986, Jones et al., “Replacing the complementarity determining regions in a human antibody with those from a mouse”.
Hird et al. Chapter 12, From: Genes and Cancer, Ed. (D. Carney et al.), Wiley and Sons, 1990, pp. 183-189.).
Harris et al., TIBTECH, 11: 42-44, 1993.
Chen et al., J. Cancer Res. Clin. Oncol., 177 p. 367-376, 1991. (Abstract only).
Liu., Chung Hug Chung Liu Tsa Chih, 10(4), pp. 242-244, 1988 (Abstract only).
Saito et al., J. Natl. Cancer Inst. 80(10), pp. 728-734, 1988. (Abstract only).
Waldman, Sci
Hirakawa Yoko
Hosokawa Saiko
Ito Norihiko
Nagaike Kazuhiro
Tagawa Toshiaki
Mitsubishi Chemical Corporation
Schwadron Ronald B.
LandOfFree
Human monoclonal antibody specifically binding to surface... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Human monoclonal antibody specifically binding to surface..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Human monoclonal antibody specifically binding to surface... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3190559